By Ken Oh
Last Monday, the United Nations issued a statement applauding the United States and the Republic of Korea for lifting travel bans on people living with HIV/AIDS(PLWHA). The US ban had been in effect for 22 years, and the South Korean ban had been similarly entrenched. Michel Sidibe, executive director of UNAIDS, hailed the parallel policy changes as “a victory for human rights on two sides of the globe”.
January 2010
Happy New Year!
Here’s the latest from our new Brooklyn office. Please help spread the word – we’re looking for graduate and undergraduate interns for spring and summer 2010. Details all the way down.
Check out the new website launched by Paulo Longo Research Institute in honor of the International Day to End Violence Against Sex Workers (yes, there really is a day for everything), www.plri.org. The site looks like a good resource for news and information on sex work, harm reduction and human rights issues. A recent wander through the site turned up these things:
The site was just launched yesterday, so there aren’t a huge number of entries yet; hopefully these will be filled out as the site develops. It would also be great if links below the abstracts led you right to the article – some just link to the host website. Put this together with AIDSLEX, the Canadian HIV/AIDS Legal Network’s new site on AIDS law, and finding resources on AIDS and human rights online just got a little bit easier.
Today and tomorrow, December 14-15, the executive board of UNITAID will vote on whether to move forward with plans for a patent pool. A patent pool is a consortium of companies that share a license to a particular product or technology. In this case, manufacturers of AIDS drugs would give a limited number of generic manufacturers the right to produce those drugs. Competition between the generic manufacturers would then drive down the price of drugs in countries where many people currently cannot afford AIDS drugs.
Controversy has roiled over the patent pool idea since some have suggested that middle-income countries should be excluded. A lot of those countries are in Asia; see this letter from APN+, the network of people living with HIV in Asia, which clearly lays out the issues.
By Shiwei Ye
The high cost of medicines essential for the prevention, treatment and cure of many diseases makes them inaccessible to millions of patients who need them. The World Health Organization estimates this to include a third of the world’s population. In parts of Asia, the percentage may be even higher.
One of the key factors making medicines unaffordable is the current intellectual property right (IPR) regime and its prominent place in many free trade agreements. There is a dire need to reform the current international trade framework in order to provide correct and adequate incentives that can lead to need-based medical innovations and that can ensure that public health is prioritized over commercial interests.
